Apyx Medical (NASDAQ:APYX) Releases Earnings Results, Beats Estimates By $0.05 EPS

Apyx Medical (NASDAQ:APYX) issued its quarterly earnings data on Thursday. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.05, FiscalAI reports. Apyx Medical had a negative net margin of 14.78% and a negative return on equity of 76.60%. The business had revenue of $14.03 million during the quarter, compared to analysts’ expectations of $13.29 million.

Here are the key takeaways from Apyx Medical’s conference call:

• Apyx reported third-quarter revenue of $14 million, up 9% year over year, led by 17% growth in Surgical Aesthetics. OEM revenue fell 41.5%, partially offsetting that growth.
• The company said AYON’s power-liposuction rollout is underway and surgeon feedback has been positive; management sees additional growth potential as it pursues regulatory approvals in international markets, though it gave no approval timelines.
• Apyx reported positive EBITDA on a trailing 12-month basis and $0.4 million in adjusted EBITDA for the quarter, versus a loss a year earlier. Operating cash use also declined year over year, and cash stood at $25.8 million at quarter-end.
• Apyx reaffirmed 2026 revenue guidance of $59 million–$60 million and lowered its operating-expense target to $41 million–$42.5 million from less than $45 million. It now expects full-year gross margins of 63%–64%.

Apyx Medical Stock Performance

Apyx Medical stock traded up $0.46 during mid-day trading on Thursday, reaching $3.04. The company had a trading volume of 994,957 shares, compared to its average volume of 122,382. The company has a debt-to-equity ratio of 3.19, a current ratio of 5.68 and a quick ratio of 4.53. Apyx Medical has a 52 week low of $2.25 and a 52 week high of $5.08. The company has a 50 day moving average of $2.74 and a 200-day moving average of $3.59.

Apyx Medical News Roundup

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: Q3 revenue was $14.0 million, above the $13.29 million analyst estimate, while the loss of $0.04 per share was narrower than consensus estimates of $0.07–$0.09. Surgical Aesthetics revenue grew 17%. Apyx Medical Q3 2026 financial results
• Positive Sentiment: Management tightened its 2026 operating expense target to $41 million–$42.5 million, indicating a greater focus on cost control. Apyx reaffirms guidance and tightens expense target
• Neutral Sentiment: Apyx reaffirmed 2026 revenue guidance of $59 million–$60 million, broadly in line with the $59.4 million consensus estimate. The company also reported a successful commercial launch of its AYON power liposuction handpiece. Apyx Medical Q3 2026 financial results
• Negative Sentiment: The company continued to post a quarterly loss and has negative net margins, so sustained revenue growth and expense control will be important to improving profitability.

Analyst Ratings Changes

APYX has been the topic of a number of research analyst reports. HC Wainwright initiated coverage on shares of Apyx Medical in a research note on Monday, July 13th. They issued a “buy” rating and a $7.00 target price on the stock. Maxim Group started coverage on shares of Apyx Medical in a research report on Tuesday, September 29th. They set a “buy” rating and a $6.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Apyx Medical in a report on Monday, September 21st. Finally, Zacks Research upgraded shares of Apyx Medical to a “hold” rating in a report on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Apyx Medical presently has an average rating of “Moderate Buy” and an average price target of $6.50.

Apyx Medical Company Profile

Apyx Medical Corporation develops and commercializes energy-based medical technologies for use in surgical and aesthetic procedures. The company’s platform is based on helium plasma technology, which is designed to deliver controlled energy for soft-tissue coagulation, cutting, and contraction.

Apyx Medical’s principal product line is Renuvion, a system that combines helium plasma with radiofrequency energy. Renuvion devices and handpieces are used by physicians in a range of surgical and aesthetic applications, including procedures intended to coagulate tissue and address skin laxity.